ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA”
July 22, 2019 14:00 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH
June 27, 2019 08:00 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals Receives Positive FDA Response to CRV431 Pre-IND Package for NASH
June 20, 2019 16:30 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 20, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering
June 18, 2019 08:45 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 18, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (NASDAQ:CTRV), a biopharmaceutical company focused on the...
ContraVir-Logo-Stacked-Lg (1).jpg
Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate
June 17, 2019 08:00 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 17, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B
June 11, 2019 08:30 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 11, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis
June 06, 2019 08:00 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., June 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split
May 31, 2019 08:00 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., May 31, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision
May 06, 2019 08:00 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
ContraVir-Logo-Stacked-Lg (1).jpg
ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference
April 29, 2019 08:30 ET | ContraVir Pharmaceuticals Inc.
EDISON, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...